Constellation Pharmaceuticals Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last twelve months. There are currently 9 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Constellation Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNST, but not buy additional shares or sell existing shares.
View analyst ratings for Constellation Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Constellation Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Constellation Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) released its earnings results on Sunday, May, 9th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $0.05.
View Constellation Pharmaceuticals' earnings history.

9 brokers have issued 1 year target prices for Constellation Pharmaceuticals' shares. Their forecasts range from $20.00 to $50.00. On average, they anticipate Constellation Pharmaceuticals' stock price to reach $34.33 in the next year. This suggests a possible upside of 1.0% from the stock's current price.
View analysts' price targets for Constellation Pharmaceuticals or view top-rated stocks among Wall Street analysts.

10 employees have rated Constellation Pharmaceuticals CEO Jigar Raythatha on Glassdoor.com. Jigar Raythatha has an approval rating of 100% among Constellation Pharmaceuticals' employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Constellation Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Perrigo (PRGO), Allakos (ALLK), I-Mab (IMAB), Cerevel Therapeutics (CERE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Arvinas (ARVN), TG Therapeutics (TGTX), Schrödinger (SDGR), Hypera (HYPMY), Turning Point Therapeutics (TPTX) and Reata Pharmaceuticals (RETA).
View all of CNST's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and AT&T (T).

(CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Avoro Capital Advisors LLC (6.70%), BlackRock Inc. (5.80%), Magnetar Financial LLC (3.82%), State Street Corp (3.32%), Versor Investments LP (3.32%) and Vanguard Group Inc. (3.26%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer.
View institutional ownership trends for Constellation Pharmaceuticals.

CNST stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Jennison Associates LLC, Morgan Stanley, Morgan Stanley, State Street Corp, Price T Rowe Associates Inc. MD, Deutsche Bank AG, and Goldman Sachs Group Inc.. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Emma Reeve, Group L P Column, Karen Valentine, and Mark A Goldsmith.
View insider buying and selling activity for Constellation Pharmaceuticals or view top insider-selling stocks.

CNST stock was acquired by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Versor Investments LP, Alpine Associates Management Inc., Man Group plc, Millennium Management LLC, CNH Partners LLC, Balyasny Asset Management LLC, and JPMorgan Chase & Co.. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Anthony B Evnin, and Group L P Column.
View insider buying and selling activity for Constellation Pharmaceuticals or or view top insider-buying stocks.

One share of CNST stock can currently be purchased for approximately $33.99.

Constellation Pharmaceuticals has a market capitalization of $1.63 billion. The company earns $-126,360,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

Constellation Pharmaceuticals employs 154 workers across the globe.

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

Constellation Pharmaceuticals is headquartered at 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected].